EGFR and cancer: The effect of sorafenib, bevacizumab, panitumumab, ramucirumab, sorafenib-bevacizumab, sorafenib-panitumumab and sorafenib-ramucirumab on the relative gene expression of CASPASE3, MMP-9, VEGFR2 and EGFR in HepG2 cancer cells was determined by RT-PCR using GAPDH as a normalizer (Figs. 6, 7).